Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(4):526–530. doi: 10.1038/bjc.1997.419

Stromal tenascin distribution as a prognostic marker in colorectal cancer.

U Kressner 1, G Lindmark 1, B Tomasini-Johansson 1, R Bergström 1, B Gerdin 1, L Påhlman 1, B Glimelius 1
PMCID: PMC2227978  PMID: 9275031

Abstract

A total of 169 colorectal adenocarcinomas, obtained from patients with a median follow-up of 6.5 years, were studied with immunohistochemical staining on cryosections using a monoclonal anti-tenascin antibody to evaluate the possible association between the staining patterns and tumour stage, tumour differentiation and survival. We found two different staining patterns in the tumour stroma--a diffuse stromal fibrillar staining in 92 out of 169 (54%) tumours and a subglandular staining in the remaining 77 tumours. When the entire group of patients (P < 0.01) and the group of potentially cured patients (P < 0.03) were analysed univariately, it was found that diffuse stromal fibrillar staining was associated with a shorter survival time than subglandular staining. In a multivariate analysis, the Dukes' stage and age were independent prognostic factors, whereas the tenascin expression did not retain a clear independent relationship to survival (P = 0.06). Hence, it appears that the tumour expression of tenascin may be a potential prognostic marker in colorectal cancer, in so far as a diffuse stromal fibrillar staining pattern seems to indicate an increased risk of poor outcome. However, after adjustment for age and Dukes' stage, the additional prognostic value of tenascin remains to be established in further analyses.

Full text

PDF
529

Images in this article

527Figure 1
on p.527

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bentzen S. M., Balslev I., Pedersen M., Teglbjaerg P. S., Hanberg-Soerensen F., Bone J., Jacobsen N. O., Overgaard J., Sell A., Bertelsen K. A regression analysis of prognostic factors after resection of Dukes' B and C carcinoma of the rectum and rectosigmoid. Does post-operative radiotherapy change the prognosis? Br J Cancer. 1988 Aug;58(2):195–201. doi: 10.1038/bjc.1988.192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bosman F. T. Prognostic value of pathological characteristics of colorectal cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1216–1221. doi: 10.1016/0959-8049(95)00153-a. [DOI] [PubMed] [Google Scholar]
  3. Böttger T. C., Potratz D., Stöckle M., Wellek S., Klupp J., Junginger T. Prognostic value of DNA analysis in colorectal carcinoma. Cancer. 1993 Dec 15;72(12):3579–3587. doi: 10.1002/1097-0142(19931215)72:12<3579::aid-cncr2820721206>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  4. Chiquet-Ehrismann R. Tenascin and other adhesion-modulating proteins in cancer. Semin Cancer Biol. 1993 Oct;4(5):301–310. [PubMed] [Google Scholar]
  5. DUKES C. E., BUSSEY H. J. The spread of rectal cancer and its effect on prognosis. Br J Cancer. 1958 Sep;12(3):309–320. doi: 10.1038/bjc.1958.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ekblom P., Aufderheide E. Stimulation of tenascin expression in mesenchyme by epithelial-mesenchymal interactions. Int J Dev Biol. 1989 Mar;33(1):71–79. [PubMed] [Google Scholar]
  7. Erickson H. P., Bourdon M. A. Tenascin: an extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annu Rev Cell Biol. 1989;5:71–92. doi: 10.1146/annurev.cb.05.110189.000443. [DOI] [PubMed] [Google Scholar]
  8. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  9. Hahn A. W., Kern F., Jonas U., John M., Bühler F. R., Resink T. J. Functional aspects of vascular tenascin-C expression. J Vasc Res. 1995 May-Jun;32(3):162–174. doi: 10.1159/000159090. [DOI] [PubMed] [Google Scholar]
  10. Hauptmann S., Zardi L., Siri A., Carnemolla B., Borsi L., Castellucci M., Klosterhalfen B., Hartung P., Weis J., Stöcker G. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab Invest. 1995 Aug;73(2):172–182. [PubMed] [Google Scholar]
  11. Ibrahim S. N., Lightner V. A., Ventimiglia J. B., Ibrahim G. K., Walther P. J., Bigner D. D., Humphrey P. A. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Hum Pathol. 1993 Sep;24(9):982–989. doi: 10.1016/0046-8177(93)90112-t. [DOI] [PubMed] [Google Scholar]
  12. Ikeda Y., Mori M., Kajiyama K., Haraguchi Y., Sasaki O., Sugimachi K. Immunohistochemical expression of tenascin in normal stomach tissue, gastric carcinomas and gastric carcinoma in lymph nodes. Br J Cancer. 1995 Jul;72(1):189–192. doi: 10.1038/bjc.1995.301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jass J. R., Love S. B., Northover J. M. A new prognostic classification of rectal cancer. Lancet. 1987 Jun 6;1(8545):1303–1306. doi: 10.1016/s0140-6736(87)90552-6. [DOI] [PubMed] [Google Scholar]
  14. Jen J., Kim H., Piantadosi S., Liu Z. F., Levitt R. C., Sistonen P., Kinzler K. W., Vogelstein B., Hamilton S. R. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med. 1994 Jul 28;331(4):213–221. doi: 10.1056/NEJM199407283310401. [DOI] [PubMed] [Google Scholar]
  15. Joshi P., Chung C. Y., Aukhil I., Erickson H. P. Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. J Cell Sci. 1993 Sep;106(Pt 1):389–400. doi: 10.1242/jcs.106.1.389. [DOI] [PubMed] [Google Scholar]
  16. Kressner U., Lindmark G., Gerdin B., Påhlman L., Glimelius B. Immunohistological p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res. 1996 Mar-Apr;16(2):951–957. [PubMed] [Google Scholar]
  17. Lindmark G., Bergström R., Påhlman L., Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer. 1995 May;71(5):1090–1094. doi: 10.1038/bjc.1995.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lindmark G., Gerdin B., Påhlman L., Bergström R., Glimelius B. Prognostic predictors in colorectal cancer. Dis Colon Rectum. 1994 Dec;37(12):1219–1227. doi: 10.1007/BF02257785. [DOI] [PubMed] [Google Scholar]
  19. Lindmark G., Gerdin B., Sundberg C., Påhlman L., Bergström R., Glimelius B. Prognostic significance of the microvascular count in colorectal cancer. J Clin Oncol. 1996 Feb;14(2):461–466. doi: 10.1200/JCO.1996.14.2.461. [DOI] [PubMed] [Google Scholar]
  20. Lindmark G., Glimelius B., Påhlman L., Enblad P. Heterogeneity in ploidy and S-phase fraction in colorectal adenocarcinomas. Int J Colorectal Dis. 1991 May;6(2):115–120. doi: 10.1007/BF00300207. [DOI] [PubMed] [Google Scholar]
  21. Mackie E. J., Halfter W., Liverani D. Induction of tenascin in healing wounds. J Cell Biol. 1988 Dec;107(6 Pt 2):2757–2767. doi: 10.1083/jcb.107.6.2757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mackie E. J. Tenascin in connective tissue development and pathogenesis. Perspect Dev Neurobiol. 1994;2(1):125–132. [PubMed] [Google Scholar]
  23. Moch H., Torhorst J., Dürmüller U., Feichter G. E., Sauter G., Gudat F. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathol Res Pract. 1993 Jun;189(5):510–514. doi: 10.1016/S0344-0338(11)80357-2. [DOI] [PubMed] [Google Scholar]
  24. Mulder J. W., Baas I. O., Polak M. M., Goodman S. N., Offerhaus G. J. Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer. 1995 Jun;71(6):1257–1262. doi: 10.1038/bjc.1995.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Natali P. G., Zardi L. Tenascin: a hexameric adhesive glycoprotein. Int J Cancer Suppl. 1989;4:66–68. doi: 10.1002/ijc.2910440718. [DOI] [PubMed] [Google Scholar]
  26. Newland R. C., Chapuis P. H., Smyth E. J. The prognostic value of substaging colorectal carcinoma. A prospective study of 1117 cases with standardized pathology. Cancer. 1987 Aug 15;60(4):852–857. doi: 10.1002/1097-0142(19870815)60:4<852::aid-cncr2820600422>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  27. O'Connell M. J., Schaid D. J., Ganju V., Cunningham J., Kovach J. S., Thibodeau S. N. Current status of adjuvant chemotherapy for colorectal cancer. Can molecular markers play a role in predicting prognosis? Cancer. 1992 Sep 15;70(6 Suppl):1732–1739. doi: 10.1002/1097-0142(19920915)70:4+<1732::aid-cncr2820701614>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  28. Riedl S. E., Faissner A., Schlag P., Von Herbay A., Koretz K., Möller P. Altered content and distribution of tenascin in colitis, colon adenoma, and colorectal carcinoma. Gastroenterology. 1992 Aug;103(2):400–406. doi: 10.1016/0016-5085(92)90827-l. [DOI] [PubMed] [Google Scholar]
  29. Riedl S., Bodenmüller H., Hinz U., Holle R., Möller P., Schlag P., Herfarth C., Faissner A. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer. 1995 Feb 20;64(1):65–69. doi: 10.1002/ijc.2910640113. [DOI] [PubMed] [Google Scholar]
  30. Sakai T., Kawakatsu H., Hirota N., Yokoyama T., Sakakura T., Saito M. Specific expression of tenascin in human colonic neoplasms. Br J Cancer. 1993 May;67(5):1058–1064. doi: 10.1038/bjc.1993.194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sakakura T., Kusakabe M. Can tenascin be redundant in cancer development? Perspect Dev Neurobiol. 1994;2(1):111–116. [PubMed] [Google Scholar]
  32. Schenk S., Chiquet-Ehrismann R. Tenascins. Methods Enzymol. 1994;245:52–61. doi: 10.1016/0076-6879(94)45005-6. [DOI] [PubMed] [Google Scholar]
  33. Shoji T., Kamiya T., Tsubura A., Hamada Y., Hatano T., Hioki K., Morii S. Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res. 1993 Sep;55(3):295–297. doi: 10.1006/jsre.1993.1143. [DOI] [PubMed] [Google Scholar]
  34. Siri A., Knäuper V., Veirana N., Caocci F., Murphy G., Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem. 1995 Apr 14;270(15):8650–8654. doi: 10.1074/jbc.270.15.8650. [DOI] [PubMed] [Google Scholar]
  35. Ståhle E., Glimelius B., Bergström R., Påhlman L. Preoperative serum markers in carcinoma of the rectum and rectosigmoid. I. Prediction of tumour stage. Eur J Surg Oncol. 1988 Aug;14(4):277–286. [PubMed] [Google Scholar]
  36. Sugawara I., Hirakoshi J., Masunaga A., Itoyama S., Sakakura T. Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. Invasion Metastasis. 1991;11(6):325–331. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES